Display options
Cite
Rosengren AM, Karlsson BC, Nicholls IA. Monitoring the distribution of warfarin in blood plasma. ACS Med Chem Lett. 2012;3(8):650-2doi: 10.1021/ml300112e.
Rosengren, A. M., Karlsson, B. C., & Nicholls, I. A. (2012). Monitoring the distribution of warfarin in blood plasma. ACS medicinal chemistry letters, 3(8), 650-2. https://doi.org/10.1021/ml300112e
Rosengren, Annika M, et al. "Monitoring the distribution of warfarin in blood plasma." ACS medicinal chemistry letters vol. 3,8 (2012): 650-2. doi: https://doi.org/10.1021/ml300112e
Rosengren AM, Karlsson BC, Nicholls IA. Monitoring the distribution of warfarin in blood plasma. ACS Med Chem Lett. 2012 Jun 20;3(8):650-2. doi: 10.1021/ml300112e. eCollection 2012 Aug 09. PMID: 24900525; PMCID: PMC4025853.
Copy Download .nbib Format: NLM
Share it on

ACS Med Chem Lett. 2012 Jun 20;3(8):650-2. doi: 10.1021/ml300112e. eCollection 2012 Aug 09.

Monitoring the distribution of warfarin in blood plasma.

ACS medicinal chemistry letters

Annika M Rosengren, Björn C G Karlsson, Ian A Nicholls

Affiliations

  1. Bioorganic and Biophysical Chemistry Laboratory, School of Natural Sciences, Linnæus University , SE-391 82 Kalmar, Sweden ; SensiKal AB , Öltappargränd 10, SE-393 64 Kalmar, Sweden.
  2. Bioorganic and Biophysical Chemistry Laboratory, School of Natural Sciences, Linnæus University , SE-391 82 Kalmar, Sweden ; SensiKal AB , Öltappargränd 10, SE-393 64 Kalmar, Sweden ; Department of Chemistry, Uppsala University , SE-751 23 Uppsala, Sweden.

PMID: 24900525 PMCID: PMC4025853 DOI: 10.1021/ml300112e

Abstract

Warfarin is an anticoagulant drug extensively used in the treatment and prevention of thrombotic disorders. Previous studies have shown that warfarin binds extensively to blood plasma proteins and that only a small fraction of the drug is unbound and thus available for therapeutic function. Both warfarin's narrow therapeutic window and the susceptibility of anticoagulant function to patient-dependent factors necessitate regular monitoring. In this study, we have shown that the lifetimes for each of the various bound and free forms of the drug in blood plasma can be quantified in situ by time-correlated single-photon counting fluorescence spectroscopy over the clinically significant concentration range. A relationship between the blood coagulation and the distribution of fluorescence lifetimes was observed. The in situ detection of clinically relevant concentrations of warfarin in its respective bound and unbound forms could provide a prognostic tool for use in patient treatment.

Keywords: TCSPC; coagulation; fluorescence spectroscopy; plasma; warfarin

References

  1. Biochem Biophys Res Commun. 2011 Apr 8;407(2):318-20 - PubMed
  2. Biochem Biophys Res Commun. 2011 Apr 1;407(1):60-2 - PubMed
  3. J Med Chem. 2010 Nov 25;53(22):7932-7 - PubMed
  4. Thromb Res. 2003;111(4-5):281-4 - PubMed
  5. J Phys Chem B. 2007 Sep 6;111(35):10520-8 - PubMed
  6. Am J Med. 1993 Sep;95(3):315-28 - PubMed
  7. Lancet. 1959 Nov 7;2(7106):754-8 - PubMed
  8. Anal Bioanal Chem. 2011 Oct;401(7):2187-93 - PubMed
  9. Nature. 2004 Feb 5;427(6974):541-4 - PubMed
  10. Nature. 2004 Feb 5;427(6974):537-41 - PubMed
  11. Clin Pharmacol Ther. 1976 May;19(5 Pt 1):552-8 - PubMed
  12. Br J Clin Pharmacol. 1992 Dec;34(6):509-12 - PubMed
  13. Biomed Chromatogr. 2012 Jan;26(1):6-11 - PubMed
  14. J Phys Chem B. 2009 Jun 4;113(22):7945-9 - PubMed
  15. Chest. 2004 Sep;126(3 Suppl):204S-233S - PubMed
  16. J Mol Recognit. 2010 Nov-Dec;23(6):604-8 - PubMed

Publication Types